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Abstract
O-sulfotransferases (OSTs) are critical enzymes in the cellular biosynthesis of the biologically and
pharmacologically important heparan sulfate and heparin. Recently, these enzymes have been
cloned and expressed in bacteria for application in the chemoenzymatic synthesis of
glycosaminoglycan-based drugs. OST activity assays have largely relied on the use of
radioisotopic methods using [35S] 3'-phosphoadenosine-5'-phosphosulfate and scintillation
counting. Herein, we examine alternative assays that are more compatible with a
biomanufacturing environment. A high throughput microtiter-based approach is reported that
relies on a coupled bienzymic colorimetric assay for heparan sulfate and heparin OSTs acting on
polysaccharide substrates using arylsulfotransferase-IV and p-nitrophenylsulfate as a sacrificial
sulfogroup donor. A second liquid chromatography-mass spectrometric assay, for heparan sulfate
and heparin OSTs acting on structurally defined oligosaccharide substrates, is also reported that
provides additional information on the number and positions of the transferred sulfo groups within
the product. Together, these assays allow quantitative and mechanistic information to be obtained
on OSTs that act on heparan sulfate and heparin precursors.
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Glycosaminoglycans (GAGs) are linear polysaccharides that are found ubiquitously in
intracellular and extracellular domains [1]. GAGs are divided among four unique families:
heparan sulfate, chondroitin sulfate, keratan sulfate, and hyaluronan. These families are
differentiated by composition, structure, and the number of sulfo groups that they carry [2].
These differences lead to highly specific roles in human biology, including but not limited to
GAG-protein binding [3,4], structural GAGs [5,6], cell adhesion and cell-cell interactions
[7], and morphogenesis [8].
Heparin is the most highly sulfated member of the heparan sulfate family of GAGs and is a
GAG of substantial biological interest, primarily because of its binding to many proteins.
One of the most important biological functions of heparin is its capacity to bind to the serine
protease inhibitor, antithrombin III (AT) [9] and inhibit the coagulation pathway. In the
coagulation cascade, prothrombin is enzymatically cleaved by Factor Xa to form thrombin,
which in turn, acts on fibrinogen to form a fibrin clot. AT inhibits this pathway by binding to
Factor Xa, preventing the formation of thrombin and ultimately the formation of fibrin. The
heparin-AT complex binds to Factor Xa with very high affinity (107 M−1 s−1) making this
complex a potent inhibitor of the coagulation pathway [10]. Heparin also forms a ternary
complex with ATIII and thrombin, inhibiting thrombin activity and preventing blood
coagulation [11].
The in vivo biosynthesis of heparin requires enzymatic catalysis resulting in: (1) formation
of the heparosan backbone on the serine-linked tetrasaccharide of the serglycin core protein
through the action of polysaccharide synthases; (2) N-deacetylase, N-sulfotransferase
(NDST)-1 and NDST-2 catalyzed N-deacetylation, N-sulfonation of the glucosamine
residues; (3) the formation of iduronic acid residues from glucuronic acid residues by C5-
epimerase (C5-epi); (4) the 2-O-sulfonation of iduronic acid residues by 2-O-
sulfotransferase (2-OST); and (5) the 6-O-sulfonation by 6-O-sulfotransferases (6-OSTs)
and 3-O-sulfonation by 3-O-sulfotransferase-1 (3-OST-1) of glucosamine residues.
Commercial heparins are derived from a number of different animal tissues and can vary
with regard to sulfonation extent and molecular weight [12].
There is a major concern about the conditions used to isolate and purify many commercial
heparins. Heparin production involves steps that occur at the slaughterhouse that are not
performed under current good manufacturing practices (cGMP). These steps greatly increase
the risk of the introduction of impurities, contamination or adulteration, a clear hazard to the
recipients of these heparin-containing products [13]. Such manufacturing pitfalls increase
the demand for a safer heparin product produced entirely under cGMP protocols. Our
laboratory is investigating a fermentative-chemoenzymatic approach for the preparation of
bioengineered heparins.
Under a bioengineering approach to the production of heparin, the heparosan backbone, a
repeating →1)-β-D-GlcA(1→4)-β-D-GlcNAc(1→ disaccharide, where GlcA is glucuronic
acid and GlcNAc is N-acetylglucosamine, is produced by fermentation of E. coli K5 on
glucose and ammonium chloride [14]. Heparosan is then converted to an N-sulfoheparosan,
with a major repeating →1)-β-D-GlcA(1→4)-β-D-GlcNS(1→ (where S is sulfo) disaccharide
structure, by enzymatic [15] or by chemical means [16]. Enzymatic conditions rely on
treating heparosan with NDST enzymes, which N-deacetylate the GlcNAc residue and N-
sulfonate the resulting amino group. Chemical conditions begin with harsh basic conditions
for N-deacetylation of heparosan followed by chemical N-sulfonation using sulfur trioxide
trimethylamine complex. The remaining enzymatic steps are believed to be identical to those
in vivo: C5-epimerization of the N-sulfoheparosan converting most of the β-D-GlcA residues
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to α-L-iduronic acid (α-L-IdoA) residues, followed by the 2-O-sulfonation of the IdoA
residues to IdoA2S, the 6-O-sulfonation of GlcNS to GlcNS6S residues, and finally 3-O-
sulfonation of a small percentage of the GlcNS6S and GlcNAc to GlcNS3S6S and
GlcNAc3S residues, respectively (Fig. 1). The primary differences between the in vivo
biosynthesis and the plant scale bioengineering of heparin are in the elongation of the
heparosan backbone and the N-sulfonation of the backbone. In vivo, the heparosan backbone
is elongated by KfiA, KfiB, KfiC, and KfiD enzymes in Escherichia coli (17) and in animals
by Ext enzymes, in which case the backbone is subsequently N-deacetylated and N-
sulfonated enzymatically by NDST enzymes (18). In bioengineered heparin, the heparosan
backbone is formed by E. coli K5 fermentation, then N-deacteylated with sodium hydroxide
and N-sulfonated using sulfur trioxide methylamine. Finally, in both the biosynthesis and
fermentative chemoenzymatic synthesis of heparin O-sulfonation is accomplished using O-
sulfotransferases (OSTs).
A major challenge to prepare a bioengineered heparin has been the development of assays to
readily assess the activity of OSTs [19]. Commonly used radioisotopic assays pose problems
for routine use in a quality control laboratory of a manufacturing facility [19]. The most
accurate and reliable method of analyzing the bioengineered enzyme activity is nuclear
magnetic resonance spectroscopy, which is time consuming, requiring added steps for
product isolation and purification prior to analysis, and requires sophisticated
instrumentation, making it potentially very useful [20, 21], but challenging for the routine
assessment of enzyme activity.
Sulfonation reactions are also being increasingly recognized as important in the metabolism
of drugs, hormones, carcinogens, neurotransmitters, lipids, and peptides [22]. Essential to
understanding these metabolic sulfotransferases is the development of robust enzyme
activity assays. Sulfotransferase assays have been the subject of a recent review that
reported the most commonly used assay to be based on the measurement by scintillation
counting of radioactive sulfate incorporated from PAP35S [19]. While these assays are
widely used and very sensitive they are also hazardous, expensive, do not provide
information on the position and number of incorporated sulfo groups, and have not been
widely used to determine kinetic information.
The current study offers two advances in OST assay method development. The first is a real-
time colorimetric method for the evaluation of heparin OST activity using a coupled enzyme
system, and the ability to obtain quantitative information on OST substrate specificities. In
this assay, a recycling enzyme, aryl-sulfotransferase IV (AST-IV), takes the 3’-adenosine
5’-phosphate (PAP) product of the OST reaction and recycles it into the 3’-adenosine 5’-
phosphosulfate (PAPS) cofactor (Fig. 2) using an additional sulfate donor, p-nitrophenyl
sulfate (PNPS). One of the products of this reaction, p-nitrophenol (PNP), is visible and can
be measured spectrophotometrically over time.
Since this coupled systems offers an indirect measurement, a second method, relying on
hydrophilic interaction liquid chromatography (HILIC)-Fourier transform mass
spectrometry (FTMS), was developed to assess heparin OST enzyme activity directly based
on measuring the products formed using defined substrates of various chain lengths. This
lower throughput method is accurate, and does not require workup steps usually required by
other mass spectrometric methods. The HILIC- FTMS method is also useful for obtaining
mechanistic information about the OSTs and exact location and number of sulfo groups
introduced.
Sterner et al. Page 3















Heparosan was produced through the large-scale fermentation of E. coli K5, a capsular K5
antigen corresponding to a polysaccharide comprised of GlcA and GlcNAc in a 1:1 molar
ratio [23]. This product, with a molecular weight of nearly 70 kDa, was chemically de-N-
acetylated using NaOH and chemically N-sulfonated using a sulfur trioxide trimethylamine
complex (Sigma Aldrich, St. Louis, MO) [12]. The resultant N-sulfoheparosan typically has
a molecular weight range of 10–16 kDa with 85% N-sulfo groups and 15% residual N-acetyl
groups. PAP and PNPS were purchased from Sigma. PAPS was prepared according to
previously published methods [24, 25].
The following enzymes and appropriate expression vectors and bacterial expression cells,
prepared as previously described [26]. These enzymes include rat AST-IV (EC 2.8.2.1) in
pET15 expression vector and BL21 expression cells; human C5-epimerase (NCBI:
NM_015554.1), mouse 6OST isoform 1 (NCBI: NM_015818.2), and mouse 6OST isoform
3 (NCBI: NM_015820.3) in pMAL-c2x expression vector and Rosetta-gami-B with GroEL
expression cells; hamster 2-OST (GenBank: D88811.1) in pMAL-c2x expression vector and
Rosetta-gami-B expression cells; mouse 3OST-1 (NCBI: NM_010474.2) in pET28
expression vector and BL21(DE3)RIL expression cells. AST-IV and 3OST-1 possess N-
terminal (His)6 tags. C5-epi, 2-OST, 6OST-1, and 6OST-3 possess N-terminal maltose
binding protein tags. A recombinant 6OST-3 prepared in CHO cells was obtained from
R&D Systems (Minneapolis, MN) and used where indicated for comparative purposes.
Heparin lyases I, II, and III were cloned from the genomic DNA of Flavobacterium
heparinum and the expression and purification of the recombinant heparin lyases was
carried out in E. coli as previously described [27].
Enzyme preparation, purification, and quantification
Cells on agar plates were selected and grown for 16 h in 5 ml of lysogeny broth media in 14
ml BD Falcon tubes, supplemented with the appropriate antibiotics. The 5 ml culture was
then transferred to a baffled 2.8-L Erlenmeyer flask containing 1-L of lysogeny broth media
and the appropriate antibiotics. The cultures were incubated at 37°C and shaken at approx.
180 RPM until the solution optical density at 600 nm reached 0.7–0.9 absorbance units. At
this point, the flask was transferred to an incubator shaker at 22°C and 180 RPM. After 30
min, the first inducer was added to the culture. If necessary, the second inducer was added
after an additional 20 min. The flask was then shaken for 20 h.
After incubation was completed, the 1-L solution was centrifuged using a Sorvall centrifuge
from Thermo Scientific (Rockland, IL) at 3500 × g for 30 min at 4°C. The supernatant was
discarded and the cell pellet was re-suspended in 20 ml of buffer, containing 25 mM Tris
(pH 7.4) and 500 mM NaCl for C5-epimerase, 2-OST, and 6-OST isoforms 1 and 3, or
containing 25 mM Tris (pH 7.4), 500 mM NaCl, and 30 mM imidazole for AST-IV and 3-
OST isoform 1. The re-suspended solution was sonicated using a Misonix 3000
(Farmingdale, NY) sonicator at 30 W and 50% cycle (15 s on, 15 s off) for a 3 min total on
time. The sonicated solution was then centrifuged at 9400 × g for 60 min at 4°C. The
supernatant was retained and the cell pellet was discarded.
The supernatant was passed through a Millipore (Billerica, MA) 0.45 µm sterile filter in
preparation for affinity isolation and purification. A 20 ml gravity-flow column was washed
3-times with 20 ml distilled water, followed by the loading of 3 ml of Ni-NTA resin from
GE Healthcare (Piscataway, NJ) or 5 ml of twice with 15 ml of washing buffer, containing
25 mM Tris (pH 7.4) and 500 mM NaCl for amylose, or containing 25 mM Tris (pH 7.4),
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500 mM NaCl, and 30 mM imidazole for Ni-NTA. The solutions containing the free
enzymes were then passed through the resin, followed by clearing of unbound material from
the resin with an additional 10 ml of washing buffer. Finally, the bound enzymes were
released from the resins using elution buffer, containing 25 mM Tris (pH 7.4), 500 mM
NaCl, and 40 mM maltose for amylose, or containing 25 mM Tris (pH 7.4), 500 mM NaCl,
and 300 mM imidazole for Ni-NTA.
Following elution, the enzymes were buffer-exchanged from Tris-buffer containing high
concentrations of imidazole or maltose to standard phosphate buffered saline (pH 7.0) by
centrifugation in Millipore (Ipswich, MA) Centrifugal Filter Units with a molecular weight
cutoff of 3000 Da. Enzyme solutions were centrifuged at 3500 × g and re-suspended in
phosphate buffered saline. Solution protein concentrations were determined by the
bicinchoninic acid assay, purchased from Thermo Scientific (Rockland, IL), against a
bovine serum albumin standard. Protein purity was determined by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis: enzyme solution was denatured at 100°C, mixed with
loading dye in a 1:1 ratio, and loaded into 4–15% polyacrylamide gels purchased from Bio-
Rad Life Sciences (Hercules, CA). Gels were run at 30 volts for 90 min in running buffer
(25 mM Tris, 192 mM glycine, 0.1% sodium dodecyl sulfate). Molecular weights were
verified by Precision Plus Protein™ All Blue Standards purchased from Bio-Rad.
Preparation of defined substrates for HILIC-MS method
A partial digestion of heparosan polysaccharide was carried out to ~ 40% completion over
17 min at room temperature [28, 29]. Heparosan (23 mg at 1 mg/ ml) was mixed with 0.28
units (1 ml) of purified heparin lyase III in 50 mM sodium phosphate (pH 7.6). The total
reaction volume was 528 ml. The digestion was stopped by heating at 100°C for 10 min.
The reaction was then repeated at a 600 mg scale of heparosan. The digested polysaccharide
was resolved on a BioGel P-10 column, which was eluted with a buffer containing 0.2 M
NaCl at a flow rate of 2 ml /h. The fractions were visualized by UV spectroscopy at 232 nm.
The resultant oligosaccharides were desalted on a BioGel P-2 column. N-sulfoheparosan
(250 mg), containing 100% GlcNS, was also digested following the same reaction protocol,
and the reaction products were also resolved on a BioGel P-10 column and desalted on a
BioGel P-2 column. The substrates were then characterized to confirm oligosaccharide
structure and purity. Analysis was performed by mass spectrometry and nuclear magnetic
resonance spectroscopy. The resulting heparosan and N-sulfoheparosan oligosaccharide
substrates ranged from degree of polymerization (dp) 2–10.
Preparation of [34S]-PAPS for HILIC-MS method
[34S]PAPS was synthesized enzymatically using a modified method from similar previously
described syntheses of [35S]PAPS by substituting Na234SO4 for Na2SO4 (from ISOFLEX
USA) [30, 31]. The reaction included 90 mM adenosine triphosphate, 100 mM MgCl2, 1 M
LiCl, 0.8 mg/ml pyrophosphatase, 0.8 mg/ml Kluyveromyces lactis expressed
arylsulfotransferase, 0.8 mg/ml adenosine-5’-phosphosulfate-3’-phosphokinase, and 50 mM
Tris-HCl at pH 8.0. The reaction was incubated at 30°C for 6 h. The [34S]PAPS product was
analyzed using HPLC (polyamine II column, YMC America, Inc.) as follows: 100% water
for 10 min, followed with a linear gradient of 0–100% of 1 M KH2PO4 for 30 min, followed
by 100% 1 M KH2PO4 for 15 min at a flow rate of 1 ml min−1 with detection at 254 nm.
Purification of PAPS was achieved on a DEAE-Sepharose fast flow column (GE Healthcare;
1.5 × 60 cm). The diethylaminoethyl column was washed with water, and PAPS was eluted
with a gradient of 0– 500 mM NaCl at 5.0 ml min−1 for 200 min. Fractions containing PAPS
as determined by HPLC on a polyamine II column were pooled and stored at −80°C. The
purity of the [34S]PAPS product was assessed by MS analysis and determined to be 90%+
with less than 10% PAP contamination) (Fig. S1, Electronic Supplementary Material).
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Colorimetric method for measuring enzyme activity
OST activity assays were carried out, unless otherwise specified, in transparent, U-bottom,
96-well plates purchased from Greiner Bio-One (Monroe, NC). A typical reaction volume of
each well was 250 µL with the following conditions: 125 µl PNPS (10 mM in phosphate
buffered saline, pH 7.0), 25 µl N-sulfoheparosan (1 mg/ml), 25 µl of an OST enzyme (400–
800 µg/ml), 25 µl AST-IV (2–3 mg/ml), 25 µl PAPS or PAP (250–500 µM), and 25 µl C5-
epi (250–500 µg/ml) or PBS. The concentrations of the substrates and the enzymes were
then varied on a case-by-case basis. The 96-well plate was incubated at 37°C in a
temperature controlled SpectraMax plate reader (Molecular Devices, Sunnyvale, CA).
Kinetic plots of p-nitrophenol (PNP) formation were generated by sample measurements at
400 nm at even time intervals over at least 30 min. Using the extinction coefficient for PNP
at pH 7.0 (at 400 nm, εPNP = 10,500 M−1cm−1), output absorbance readings from the plate
reader were converted to µM concentrations of PNP and the data were re-plotted in terms of
[PNP] as a function of time. Initial enzyme velocities (vi) were calculated as the change in
[PNP] over a linear segment of the plot. Vi values, corresponding to varied PAP, PAPS, or
enzyme concentrations, were fit to Michaelis-Menten and Eadie-Hofstee functions to yield
the kinetic parameters.
Reaction conditions for HILIC method
The activities of OSTs were assessed by incubating 5.0 µg of purified 2-OST with 2.5 µg of
N-sulfoheparosan derived decasaccharide and 2 µg PAPS in 22.5 µl of 50 mM MES buffer
pH 7.0. The reaction occurred over 24 h with aliquots removed at 0, 1, 2, 3, 4, 7, and 24 h.
Each aliquot was quenched by adding 50 µl of 100% acetonitrile.
MS analysis
The products were analyzed by HILIC using a 2.0 × 50 mm (Torrance, CA) The products
were analyzed by HILIC using a 2.0 × 50 mm Luna HILIC column (Phenomenex, Torrance,
CA) coupled to an electrospray ionization LTQ-Orbitrap XL FTMS (Thermo Fisher
Scientific, San-Jose, CA). The mobile phase A was 5 mM ammonium acetate prepared with
HPLC grade water. Mobile phase B was 5 mM ammonium acetate prepared in 98% HPLC
grade acetonitrile with 2% HPLC grade water. An Agilent 1200 HPLC binary pump was
used to deliver the gradient from 10% A to 80% A over 8 min at a flow rate of 250 µl/min
after injecting the samples. The optimized MS parameters, used to prevent in-source
fragmentation, included a spray voltage of 4.2 kV, a capillary voltage of −40 V, a tube lens
voltage of −50 V, a capillary temperature of 275 °C, a sheath flow rate of 30, and an
auxiliary gas flow rate of 6. External calibration of mass spectra routinely produced a mass
accuracy of better than 3 ppm. All FT mass spectra were acquired at a resolution 60,000
within a 400–2000 Da mass range.
Results and discussion
Approach
Each OST has two substrates, the sulfo donor PAPS and a phenol or a carbohydrate
hydroxyl acceptor. We initially examined the activity of the recycling enzyme, AST-IV,
which is critical for transferring the sulfo group from PNPS to PAP to form the PAPS
cofactor. Through the action of AST-IV, therefore, the bienzymic system can be used to
assess conversion of PNPS into the visibly detectable PNP. AST coupled assays were first
reported on NodST, an enzyme that catalyzes the formation of 6-O-sulfochitobiose [32, 33,
34]. These studies also provided an indirect measurement of NodST’s Michaelis-Menten
kinetics. Assaying the heparin OSTs adds several additional levels of complexity. First,
these enzymes act on various substrates, ranging from oligomers to polymers, which have
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multiple non-identical acceptor sites. For example, a polysaccharide substrate of molecular
weight 10,000 might have ~20 glucosamine residues, some substituted with N-acetyl groups
and some with N-sulfo groups, and ~20 uronic acid residues, some consisting of GlcA and
some IdoA. In addition, the reactivity of these residues might differ whether they are in the
center of the polysaccharide chain, at the non-reducing end or at the reducing end. Finally,
the sequence context might have a profound effect on whether or not an OST acts and to
what extent.
Coupling AST-IV to OST catalysis was then tested with all three classes of site-specific
glycan sulfotransferases; 6OST-1 and 6OST-3, 2OST, and 3OST-1. The 6OSTs are
structurally the simplest heparin biosynthetic enzymes, and are believed to act on
unmodified chains of simple structures, i.e., heparosan or N-sulfoheparosan, or slightly more
modified disaccharides, i.e., 2-O sulfonated N-sulfoheparosan, with different reactivities.
The 6OST activity assay was coupled to AST-IV to recycle PAPS, maintaining the PAP
concentration low to prevent product inhibition [35]. 2OST was examined on N-
sulfoheparosan, C5-epi-treated N-sulfoheparosan, and several defined oligosaccharide
substrates. Finally, 3OST-1 was studied on a highly modified substrate, heparan sulfate.
Each heparin OST assay was first performed on polysaccharide substrates using an AST-IV
coupled colorimetric assay to measure activity. This was then followed by the determination
of OST activity on defined oligosaccharide substrates followed by HILIC-FTMS analysis. It
is important to note that while all of the E. coli expressed recombinant OSTs used in this
study show good specificity and are catalytic, a fairly high enzyme to substrate ratio is
required. This may be the result of reduced activity do to their truncation (missing their
transmembrane domain), the presence of fusion proteins (with either (His)6- or maltose-
binding protein-tags), or the lack of glycosylation (present in the natural OSTs).
AST-IV kinetics
Rapid OST kinetic analysis requires the coupled, bienzymic recycling activity of AST-IV,
which must not be rate limiting. Therefore, we first examined the kinetics of AST-IV using
PNPS and PAP as substrates. At concentrations of PNPS and PAP of 5.0 and 0.25 mM,
respectively, the rate of PNP release was linear up to 8.5 µg/ml AST-IV (Fig. S2 (A),
Electronic Supplementary Material). The enzyme followed conventional Michaelis-Menten
kinetics with a Km for PAP of 25.3 µM with 5 mM PNPS (Fig. S2 (B), Electronic
Supplementary Material). This value is similar to that found in the literature [34, 36]. The
Vmax for PAP as substrate was 165.5 nmol/min/mg enzyme at 5 mM PNPS, similar to
literature values [37].
Assays for 6OST-1 and 6OST-3
Initial experiments revealed that 6OST-1 and 6OST-3 showed no measurable activity on
heparosan using the coupled colorimetric assay, consistent with the literature [38] and
unsurprising considering the low percentage of N-acetylated and 6-sulfonated disaccharides
present in heparin [16]. However, both enzymes were active on heparan sulfate and N-
sulfoheparosan, with activity on the former at least 2-fold higher than that on the latter,
indicating that the presence of the 2-O-sulfate and IdoA residues are favorable for 6OST
activity (Fig. S3, Electronic Supplementary Material). This reactivity was confirmed by 1H-
nuclear magnetic resonance spectroscopy (Fig. S4 (A), Electronic Supplementary Material).
Furthermore, disaccharide analysis of the action of 6OST-3 on a partially 2-O-sulfated
heparan sulfate revealed that the enzyme strongly favored the N-sulfo, 2-O-sulfo
disaccharides over the unsulfated and N-sulfo disaccharides (Fig. S4 (B), Electronic
Supplementary Material).
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We assessed the rate-limiting step in the bienzymic assay with AST-IV to obtain more
quantitative kinetics information on the 6-OSTs. At PAPS and N-sulfoheparosan
concentrations of 75 µM and 100 µg/ml, respectively, increasing the 6OST-3 activity up to
80 µg/ml, the highest 6OST-3 concentration tested, resulted in a linear increase in reaction
rate (Fig. 3). Hence, under conditions used in this work, AST-IV was not rate limiting. The
activity of 6OST-3 on N-sulfoheparosan could be increased by pre-incubating the enzyme
with C5-epi (Table 1 and Fig. 4), suggesting a preference for the action of this isoform at
GlcNS residues in close proximity to IdoA residues.
For polysaccharide substrate the enhanced reactivity of 6OST-3 due to the C5-epi was not
evident (Fig. 5A). Specifically, in the presence of 80 µg/ml 6-OST 3, the KM and Vmax
values for N-sulfoheparosan were 13.8 µg/ml and 51 nmol/(min mg enzyme), respectively.
On the C5-epimerized N-sulfoheparosan as polysaccharide substrate, the Km and Vmax
values were 14.1 µg/ml and 61.0 nmol/(min mg enzyme), respectively. While the influence
of the C5-epi was marginal on the kinetics of 6OST-3 on the polysaccharide substrate, the
kinetics with the PAPS substrate was strongly influenced by the C5-epi (Fig. 5B).
Specifically, the Km of PAPS was approx. 4-fold lower in the presence of the C5-epi (8.3 vs.
33 µM, respectively), while the Vmax values for PAPS were similar at 73.5 nmol/(min mg
enzyme) or 62.5 nmol/(min mg enzyme) with or without the C5-epi, respectively.
To further understand the influence of C5-epimerization on 6OST-3 activity, two-substrate
Michaelis-Menten kinetic analysis was performed by varying PAPS (5–40 µM) and N-
sulfoheparosan (12–100 µg/ml) concentrations, with and without 3 h pre-incubation of
6OST-3 with C5-epimerase. Under conditions where N-sulfoheparosan was preincubated
with C5-epi, the primary Lineweaver-Burk plots suggested ternary complex kinetics,
represented by coincident intersection (Figs. 6 A and B). The secondary replots against the
intercept values (Figs. 6 C and D, Table 2) afforded , kcat
= 0.2 s−1, and a kcat/KM,PAPS = 2.04 × 104 s−1 M−1 . Under conditions without C5-epi
present, ternary complex mechanism kinetics was also observed (Figs. 7 A and B).
Secondary replots against the intercept values (Figs. 7C and D, Table 2) afforded
, kcat = 0.04 s−1 , and a kcat/KM,PAPS = 1.02×103 s−1
M−1.
Based on the intersection point of the primary plots (Figs. 6 A and B, Figs. 7 A and B),
apparent dissociation constants for the PAPS and NSH substrates with 6OST-3 could be
calculated. For PAPS, the apparent dissociation constant (Ks,paps) is nearly identical between
both epimerized and non-epimerized N-sulfoheparosan (~ 15–20 µM), whereas the apparent
dissociation constant for epimerized and non-epimerized N-sulfoheparosan are distinct
(KS,EPINSH = ~66 µg/ml, KS,NSH = ~3 µg/ml). This suggests that 6OST-3 follows a kinetic
mechanism wherein an ordered ternary complex is formed, with PAPS first binding to the
enzyme followed by the binding of the N-sulfoheparosan. Following the transfer of the sulfo
group, the 6-O sulfonated N-sulfoheparosan is released followed by the PAP product. In
order to verify this order, the binding of 6OST-3 to N-sulfoheparosan was tested in the
absence of PAPS using surface plasmon resonance (SPR). As shown in Fig. S5 (Electronic
Supplementary Material), 6OST-3 was incapable of binding to N-sulfoheparosan in the
absence of PAPS, which confirms the ordered ternary complex mechanism.
Structurally defined N-sulfoheparosan oligosaccharide substrates were employed to
investigate further the reactivity and substrate specificity of 6OST-3. These experiments
initially used the commercial recombinant mouse enzyme expressed in Chinese Hamster
Ovary (CHO) cells (R&D Systems). The sequence comparison for the commercial 6OST-3
differed slightly from the E. coli expressed enzyme prepared in our laboratory (Fig. S6,
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Electronic Supplementary Material). In addition, this enzyme was glycosylated by the CHO
cells in which it had been prepared. The CHO cell expressed 6OST-3 showed greater
specific activity but identical specificity as the E. coli expressed 6OST-3 on the substrates
tested. In these studies [34S]PAPS, including the stable sulfur isotope (Fig. S1, Electronic
Supplementary Material), replaced previously used [32S]PAPS to improve the sensitivity of
the method as the product masses would increase by 2.0159 amu for each sulfo group
incorporated [39].
Activity on each individual substrate was assessed by incubating the commercial 6OST-3, or
lab prepared 6OST-3, with 50 µM of heparosan hexasaccharide, N-sulfoheparosan
tetrasaccharide, N-sulfoheparosan hexasacharide, N-sulfoheparosan octasaccharide, or N-
sulfoheparosan decasaccharide, and 120 µM [34S]PAPS in 50 mM MES buffer pH 7.0 for a
total reaction volume of 100 µl. Over 24 h, 6 µl aliquots were removed at specific time
points. Each aliquot was added to 15 µl of 100% acetonitrile to quench the reaction. The
samples were then analyzed and the sum of the sulfonated products was plotted. The
sulfonation of an N-sulfoheparosan tetrasaccharide over time is presented in Fig. 8. The
addition of one sulfo or two sulfo groups was monitored and the initial rates were converted
into molar activity.
A summary of the activities based on varying chain lengths of substrate is presented in Table
3. No activity was observed on the heparosan hexasaccharide, consistent with the
aforementioned lack of 6OST activity on heparosan. The N-sulfo tetrasaccharide was a poor
substrate, while the N-sulfo hexasaccharide, N-sulfo octasaccharide, and N-sulfo
decasaccharide showed similar activities suggesting a minimum chain length requirement.
The crystal structure of 6OST-3 has not been determined, and hence, the binding sites are
unknown. However, these data might help to clarify its substrate specificity.
Assays for 2OST
As with 6OSTs, we determined 2OST to be rate limiting in the coupled reaction with AST-
IV (data not shown). 2OST showed no measurable activity on either heparosan or N-
sulfoheparosan. However, addition of C5-epimerase, resulted in the introduction of IdoA
residues into N-sulfoheparosan, and formation of measurable activity of 2OST (Fig. S3,
Electronic Supplementary Material), as confirmed using both disaccharide compositional
analysis (Fig. S7, Electronic Supplementary Material) and nuclear magnetic resonance
spectroscopy (Fig. S4 (A), Electronic Supplementary Material). Treatment of N-
sulfoheparosan with C5-epimerase and 2OST afforded new peaks in the 1H-nuclear
magnetic resonance spectroscopy at 3.9, 4.2, 4.3 and 5.2 ppm, corresponding to signals
associated with IdoA2S [12]. These results are consistent with the reported preference of
2OST for IdoA containing substrates [40].
We proceeded to evaluate the activity of 2OST on an epimerized N-sulfoheparosan
substrate. The concentrations of the GAG and OST were increased above those used in the
6OST assay to generate a robust response. Under varied PAPS concentrations, maintaining a
constant epimerized N-sulfoheparosan concentration of 0.5 mg/ml and a 2-OST
concentration of 0.25 mg/ml, the Vmax and KM values were calculated to be 35.1 µM and
288 pmol/min mg enzyme, respectively (Fig. 9). These values were similar to those reported
in literature [41] for 2OST activity on completely de-O-sulfated heparin (CDSHP), a
substrate that lack all O-sulfonations, but possesses the IdoA residues and N-sulfonations
critical for 2OST activity.
Finally, we examined 2OST activity on the structurally defined N-sulfoheparosan
decasaccharide substrate to confirm 2OST activity on GlcA residues. The N-sulfoheparosan
decasaccharide substrate showed a peak in its mass spectra at m/z 694.08 ([M-3H]3-, z = −3,
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MW 2085.2886) that disappeared over time with the appearance of a mono-2-O-sulfo-N-
sulfoheparosan decasaccharide product peak at m/z 720.739 ([M-3H]3-, z = −3, MW
2165.2454) after 1 h, di-2-O-sulfo-N-sulfoheparosan decasaccharide product peak at m/z
747.397 ([M-3H]3-, z = −3, MW 22.45.2022) after 1 h, and tri-2-O-sulfo-N-sulfoheparosan
decasaccharide product peak at m/z 774.049 ([M-3H]3-, z = −3, MW 2325.159) after 7 h
(Fig. 10A). The peak area of each sulfonated product was determined and compared with the
peak area of the known concentration of substrate to calculate the concentration of each
product as a function of time (Fig. 10B), assuming similar ionization efficiencies. The sum
of the sulfonated products was also plotted and its linear region (up to 5 min) was used to
estimate an enzyme activity of 0.33-pmol product formed·min−1, with a specific activity of
131-pmol product formed·min−1·mg−1 protein. It is important to note that loss of 0.1–10% of
sulfo groups can take place through in source fragmentation increasing with the level of
sulfo group substitution. Since LC-MS analysis affords different retention times for
oligosaccharides with differing levels of sulfation, in source fragmentation can be clearly
distinguished from an analyte containing oligosaccharides having different sulfation levels.
Assays for 3OST-1
3OST-1 is responsible for installing the AT-pentasaccharide binding site into approx. one-
third of the heparin chains [11], and thus, recognizes a rare sequence within the precursor
substrate structure [42]. 3-OST-1 acts on a polysaccharide containing the sequence: →4) α-
D-GlcNY (1→4) α-/β-D-GlcA/L-IdoA (1→4) α-D-GlcNY6X (1→4) β-D-GlcA (1→4) α-
D-GlcNS6X (1→4) α-L-IdoA2S (1→4) α-D-GlcN6S(1→4)α/β-D-GlcA/L-IdoA2X (1→
(where Y = Ac or S and X = H or S, bold residues correspond to the AT-pentasaccharide
binding site and bold/italicized residue is the one that will be sulfonated at the 3-position by
3-OST-1). No measurable activity was observed for 3OST-1 acting on heparosan or N-
sulfoheparosan using the coupled colorimetric assay. The more highly modified heparan
sulfate polysaccharide, however, is known to act as a substrate for 3OST-1 converting a low
AT affinity heparan sulfate into a high affinity chain [11, 42]. A 3OST-1 assay, using
coupled AST-IV (Fig. 11), afforded a PAPS KM for 3OST-1 of 13.5 µM, consistent with
previously published literature using radioisotopic methods [43]. In addition, heparin lyase
II treatment followed by LC-MS analysis of the resulting high AT affinity heparan sulfate
confirmed the formation of a 3-O-sulfo group containing tetrasaccharide consistent with the
generation of an AT pentasaccharide binding site (Fig. S8, Electronic Supplementary
Material).
Conclusions
We have outlined two assays for the real-time and near real-time analysis of heparan sulfate
sulfotransferase enzyme activity. Under real-time conditions, a colorimetric methodology
was used, coupling the OSTs with an AST-IV enzyme to produce a visibly measurable
product. This method was also coupled with the C5-epi to gauge the importance of iduronic
acid residues in OST bioactivity. Robust colorimetric assays were run with 6OST-3, to
determine detailed kinetic parameters, and products were verified by LC-MS and nuclear
magnetic resonance spectroscopy. Variations of PAPS concentration and epimerization of
GlcA into IdoA residues had a significant effect on 6OST-3 and 2OST kinetics, but no
obvious effect was seen under conditions of varied N-sulfoheparosan concentration. In the
near real-time methodology, hydrophilic interaction chromatography was used with a
defined substrate to measure the overall additions of sulfo groups to the substrate.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CDSNS HP Completely de-O-sulfonated heparin
cGMP Current good manufacturing process
C5-epi C5 Epimerase
















3-OST-1 3-O sulfotransferase isoform 1
6-OST-1 6-O sulfotransferase isoform 1
6-OST-3 6-O sulfotransferase isoform 3
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Chemoenzymatic synthesis of heparin. Fermentation of E. coli K5 on glucose and ammonia
affords heparosan which is then treated with sodium hydroxide to remove over 80% of its N-
acetyl groups reduce its molecular weight to afford an N-sulfoheparosan. The N-
sulfoheparosan is then converted through a series of enzymatic steps using C5-Epi, 2OST,
6OST-1 and −3 and 3OST-1 to form bioengineered heparin. The structure of an AT-
pentasaccharide binding site is shown as the final product. These enzymatic steps closely
parallel the final steps within heparin biosynthesis.
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Schematic outlining the aryl-sulfotransferase/O-sulfotransferase coupled assay. In a system
initialized with PAPS, the O-sulfotransferase converts PAPS to PAP and sulfates the GAG.
PAP is then recycled to PAPS by aryl-sulfotransferase with p-nitrophenylsulfate (R = NO2)
acting as the sulfate donor. The products of the arylsulfotransferase reaction are PAPS,
which is reused with the OST enzyme, and p-nitrophenol, PNP, which is measureable
spectrophotometrically.
Sterner et al. Page 15














Effect of 6OST-3 concentration on rate of 6-O-sulfonation with (Δ) and without (□) pre-
incubation with C5-epi. The polysaccharide substrate concentration was kept between 0.1
and 0.25 mg/mL and the enzyme substrate ration was < 1:1.
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Time course comparison of the action of 6OST-3 and 2OST on N-sulfoheparosan is shown
in the presence and absence of C5-Epi. 2OST only (○); 2OST, C5-epimerase (□); 6OST-3
only (Δ); 6OST-3, C5-epimerase (∇).
Sterner et al. Page 17














Michaelis-Menten kinetics (Eadie-Hofstee plot as Inset) of 6OST-3 on N-sulfoheparosan.
(A) As a function of N-sulfoheparosan concentration with (Δ) and without (□) preincubation
with C5-epi. (B) As a function PAPS concentration with (Δ) and without (□) preincubation
with C5-epi.
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Dual-substrate kinetics of 6OST-3 on C5-epi treated N-sulfoheparosan. (A) Primary
Lineweaver-Burk plot with respect to [N-sulfoheparosan]−1. (B) Primary Lineweaver-Burk
plot with respect to [PAPS]−1. (C) Secondary replot of intercepts against [PAPS]−1. (D)
Secondary replot of intercepts against [N-sulfoheparosan]−1.
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Dual-substrate kinetics of 6OST-3 in the absence of C5-epi treated N-sulfoheparosan. (A)
Primary Lineweaver-Burk plot with respect to [N-sulfoheparosan]−1. (B) Primary
Lineweaver-Burk plot with respect to [PAPS]−1. (C) Secondary replot of intercepts against
[PAPS]−1. (D) Secondary replot of intercepts against [N-sulfoheparosan]−1.
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The 6OST-3 catalyzed sulfonation of N-sulfoheparosan to form one (○) or two (□) sulfo
groups, total product formed (Δ), as determined by HILIC-MS.
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Michaelis-Menten kinetics (Eadie-Hofstee plot as Inset) of 2OST on completely de-O-
sulfonated heparin.
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(A) Time course of 2-O-sulfonation of N-sulfo decasaccharide. The increasing amounts of
mono-, di- and tri-sulfonated products were calculated from the HILIC-MS data. (B) Time
course of N-sulfoheparosan (∇) 2-O-sulfonation, from the addition of one sulfo (○), two
sulfo (□), or three sulfo groups (Δ), total product formed (◊), as determined by HILIC-MS.
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Michaelis-Menten kinetics (Eadie-Hofstee plot as Inset) of 3OST-1 on heparan sulfate.
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Table 1
Initial reaction rates for O-sulfotransferases on N-sulfoheparosan.
Reaction Conditions Velocity (nmol/min mg OST)
2OST 0.00 ± 0.85
2OST & C5-Epi 1.63 ± 0.80
6OST3 45.1 ± 1.04
6OST3 & C5-Epi 86.4 ± 0.89
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Table 3






NS hexasaccharide (Lab Prep. 6OST-3) 10.94
NS octasaccharide 19.07
NS decasaccharide 14.01
Heparosan hexasaccharide No Reaction (<0.01)
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